- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05132088
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity (OASIS 2)
Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in East Asian Participants With Overweight or Obesity
Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight.
This study will look at the change in participants' body weight. Participants will either get semaglutide tablets (new medicine) or placebo tablets ('dummy' medicine that looks like semaglutide but has no effect on the body). For a fair comparison, people are divided into two groups at random by a computer. This process is called randomisation.
Semaglutide tablets are new medicine being tested to treat overweight and obesity. Doctors in many countries can already prescribe semaglutide tablets at lower doses to treat type 2 diabetes.
Participants will get semaglutide or placebo tablets for 68 weeks and will need to take 1 tablet every morning.
In addition to taking the medicine, participants will have talks with study staff about:
- healthy food choices
- how to be more physically active
- what participants can do to lose weight The study will last for about 1½ year. Participants will have 14 clinic visits and 7 phone calls with the study healthcare professional.
Blood samples will be taken at 12 visits. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period. If participants are a woman and are able to become pregnant, participants will be checked for pregnancy via urine tests.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Ibaraki, Japan, 311-0113
- Novo Nordisk Investigational Site
-
Minato-ku, Tokyo, Japan, 105-8470
- Novo Nordisk Investigational Site
-
Osaka, Japan, 569-1045
- Novo Nordisk Investigational Site
-
Osaka, Japan, 565-0871
- Novo Nordisk Investigational Site
-
Tokyo, Japan, 103-0028
- Novo Nordisk Investigational Site
-
Tokyo, Japan, 160-0008
- Novo Nordisk Investigational Site
-
-
Hokkaido
-
Sapporo city, Hokkaido, Japan, 004-0004
- Novo Nordisk Investigational Site
-
-
Kanagawa
-
Yamato-shi, Kanagawa, Japan, 242-0004
- Novo Nordisk Investigational Site
-
-
Osaka
-
Suita-shi, Osaka, Japan, 565-0853
- Novo Nordisk Investigational Site
-
-
-
-
-
Daegu, Korea, Republic of, 41944
- Novo Nordisk Investigational Site
-
Gyeonggi-do, Korea, Republic of, 13620
- Novo Nordisk Investigational Site
-
Incheon, Korea, Republic of, 21565
- Novo Nordisk Investigational Site
-
Seoul, Korea, Republic of, 03181
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
Participants are eligible to be included in the study only if all the following criteria apply:
- Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- Male or female, age above or equal to 18 years at the time of signing informed consent
- Body mass index (BMI) of greater than or equal to 27.0 kg/m^2 with greater than or equal to 2 weight related comorbidities (treated or untreated) according to the JASSO guideline or BMI greater than or equal to 35.0 kg/m^2 with greater than or equal to1 weight related comorbidity (treated or untreated) according to the JASSO guideline. At least one comorbidity should be hypertension, dyslipidaemia or type 2 diabetes (T2D)
- History of at least one self-reported unsuccessful dietary effort to lose body weight
For participants with T2D at screening the following inclusion criteria apply in addition to criteria 1-4:
- Diagnosed with T2D greater than or equal to 180 days prior to screening
- Treated with either diet and exercise alone or stable treatment (same drug(s), dose and dosing frequency) for at least 60 days prior to the day of screening with up to 3 oral antidiabetic drugs (OADs) alone or in any combination (metformin, α-glucosidase (AGI), sulphonylureas (SU), glinides, SGLT2i (sodium-glucose co-transporter 2 inhibitor) or thiazolidinediones)
- HbA1c 7.0-10.0% (53-86 mmol/mol) (both inclusive) as measured by central laboratory at screening
Exclusion criteria:
Participants without T2D only:
- HbA1c greater than or equal to 6.5% (48 mmol/mol) as measured by the central laboratory at screening
- History of type 1 or type 2 diabetes
- Treatment with glucose-lowering agent(s) within 90 days prior to screening
- Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of eGFR brlow 15 ml/min/1.73 m^2 according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by kidney disease improving global outcomes (KDIGO) 2012 classification by the central laboratory at screening
Participants with T2D at screening only:
- Treatment with any medication for the indication of diabetes other than stated in the inclusion criteria within the past 60 days prior to screening
- Receipt of any other anti-diabetic investigational drug within 90 days prior to screening for this study, or receipt of any investigational drugs not affecting diabetes within 30 days prior to screening for this study
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed by an ophthalmologist or another suitably qualified health care provider within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Renal impairment measured as eGFR value of below 30 mL/min/1.73 m^2 according to CKD EPI creatinine equation as defined by KDIGO 2012 classification by the central laboratory at screening
- In participants treated with SGLT2i, renal impairment measured as eGFR value of below 60 mL/min/1.73 m^2 according to CKD EPI creatinine equation as defined by KDIGO 2012 classification by the central laboratory at screening
The following criteria apply to all participants:
Obesity-related:
- Treatment with any medication indicated for weight management within 90 days prior to screening
- Previous or planned (during the study period) obesity treatment with surgery or a weight loss device. However, the following are allowed: (1) liposuction and/or abdominoplasty, if performed greater than 1 year prior to screening, (2) lap banding, if the band has been removed greater than 1 year prior to screening, (3) intragastric balloon, if the balloon has been removed greater than 1 year prior to screening or (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed greater than 1 year prior to screening
- Uncontrolled thyroid disease per investigators discretion
- A self-reported change in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: oral semaglutide 50 mg once daily
All participants will get semaglutide or placebo tablets, 1 tablet every morning.
|
Participants will have semaglutide for 68 weeks and will have 1 tablet every morning. Dose gradually increased to 50 mg. |
Placebo Comparator: oral semaglutide placebo once daily
All participants will get semaglutide or placebo tablets, 1 tablet every morning.
|
Participants will have placebo tablets for 68 weeks and will have 1 tablet every morning.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative change in body weight
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
Percentage-point
|
From baseline (week 0) to end of treatment (week 68)
|
Achievement of body weight reduction greater than or equal to 5% (Yes/No)
Time Frame: At end of treatment (week 68)
|
Count of participants
|
At end of treatment (week 68)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Achievement of body weight reduction greater than or equal to 10% (Yes/No)
Time Frame: At end of treatment (week 68)
|
Count of participants
|
At end of treatment (week 68)
|
Achievement of body weight reduction greater than or equal to 15% (Yes/No)
Time Frame: At end of treatment (week 68)
|
Count of participants
|
At end of treatment (week 68)
|
Achievement of body weight reduction greater than or equal to 20% (Yes/No)
Time Frame: At end of treatment (week 68)
|
Count of participants
|
At end of treatment (week 68)
|
Change in lipids: Total cholesterol
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
Ratio to baseline
|
From baseline (week 0) to end of treatment (week 68)
|
Change in lipids: Triglycerides
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
Ratio to baseline
|
From baseline (week 0) to end of treatment (week 68)
|
Change in lipids: Free fatty acids
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
Ratio to baseline
|
From baseline (week 0) to end of treatment (week 68)
|
Change in Physical function domain (5-items) score (IWQOL-Lite-CT)
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
Score points
|
From baseline (week 0) to end of treatment (week 68)
|
Change in body mass index (BMI)
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
Count of participants
|
From baseline (week 0) to end of treatment (week 68)
|
Change in waist circumference measured according to the JASSO guideline
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
Messured in CM
|
From baseline (week 0) to end of treatment (week 68)
|
Change in Visceral Fat Area (VFA) measured by CT scan in a subset of the Japanese study population
Time Frame: From baseline to end of treatment (week 68)
|
%-point
|
From baseline to end of treatment (week 68)
|
Change in Visceral Fat Area (VFA) measured by CT scan in a subset of the Japanese study population
Time Frame: From baseline to end of treatment (week 68)
|
Messured in cm^2
|
From baseline to end of treatment (week 68)
|
Change in systolic blood pressure
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
Messured in mmHg
|
From baseline (week 0) to end of treatment (week 68)
|
Change in diastolic blood pressure
Time Frame: From randomisation (week 0) to end of treatment (week 68)
|
Messured in mmHg
|
From randomisation (week 0) to end of treatment (week 68)
|
Change in glycated haemoglobin (HbA1c)
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
%-point
|
From baseline (week 0) to end of treatment (week 68)
|
Change in lipids: high density lipoprotein (HDL) cholesterol
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
Ratio to baseline
|
From baseline (week 0) to end of treatment (week 68)
|
Change in lipids: low-density lipoprotein (LDL) cholesterol
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
Ratio to baseline
|
From baseline (week 0) to end of treatment (week 68)
|
Change in lipids: very-low density lipoprotein (VLDL) cholesterol
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
Ratio to baseline
|
From baseline (week 0) to end of treatment (week 68)
|
Change in high sensitivity C Reactive Protein
Time Frame: From baseline (week 0) to end of treatment (week 68)
|
Ratio to baseline
|
From baseline (week 0) to end of treatment (week 68)
|
Number of treatment emergent adverse events
Time Frame: From baseline (week 0) to end of study (week 75)
|
Count of events
|
From baseline (week 0) to end of study (week 75)
|
Number of serious adverse events
Time Frame: From baseline (week 0) to end of study (week 75)
|
Count of events
|
From baseline (week 0) to end of study (week 75)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Transparency (dept. 1452), Novo Nordisk A/S
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9932-4738
- U1111-1258-7561 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight and Obesity
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Universidade do Extremo Sul Catarinense - Unidade...RecruitingObesity | Overweight and Obesity | Obesity; Endocrine | Overweight, Obesity and Other HyperalimentationBrazil
-
Mexican National Institute of Public HealthUNICEFCompleted
-
Universidade do PortoFundação para a Ciência e a Tecnologia; Administração Regional de Saúde do... and other collaboratorsCompletedOverweight and ObesityPortugal
-
University of British ColumbiaTerminatedOverweight and ObesityCanada
-
National Taiwan University HospitalCompleted
Clinical Trials on semaglutide 50 mg
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2 | DiabetesChina
-
Sansum Diabetes Research InstituteNovo Nordisk A/STerminatedDiabetes Mellitus, Type 2 | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedObesitySpain, United States, France, Russian Federation, Canada, Colombia, South Africa, Norway, Denmark, Saudi Arabia, Sweden
-
Novo Nordisk A/SCompletedObesityKorea, Republic of, Thailand
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SActive, not recruitingNon-alcoholic SteatohepatitisSpain, Denmark, Taiwan, Korea, Republic of, Australia, Canada, India, Singapore, United States, Turkey, Poland, Italy, Belgium, Puerto Rico, United Kingdom, Malaysia, Germany, Portugal, Bulgaria, Czechia, France, Greece, Japan, Russian...